PHILADELPHIA — Each year more than 300,000 Americans will succumb to out-of-hospital sudden cardiac death (SCD) – the immediate and unexpected cessation of the heart’s ability to function properly – one of the leading causes of death in the United States. For the first time, a team of researchers led by Rajat Deo, MD, MTR, an assistant professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania, has developed and validated a prediction model to determine sudden cardiac death risk in adults without a history of cardiovascular disease (CVD). This research is detailed in a paper published in Circulation.
SCD occurs unexpectedly with little to no warning signs or symptoms and most commonly among those in the general population without a history of cardiovascular disease. The identification of specific risk models for SCD has remained a challenge particularly because individuals from the general population are at a low overall risk of SCD and large, well-defined populations are needed to develop risk scores. Deo and his colleagues set out to develop a model that could predict SCD risk among the general public.
“Sudden cardiac death is a significant public health concern, and the rates of decline have not paralleled those observed for other cardiovascular conditions such as heart attack or stroke,” said Deo, the study’s lead author.
"The American Health Association and American College of Cardiology developed a risk equation for determining generalized cardiovascular risk in 2013, but this is the first time an SCD-specific prediction model has been developed and validated.”
Researchers evaluated 17,884 adults, 45 years of age and older with no history of cardiovascular disease, who were participants in two large, National Institute of Health (NIH)-funded cohorts: the Atherosclerosis Risk in Communities (ARIC) Study and the Cardiovascular Health Study (CHS). They assessed a variety of demographics, clinical and laboratory data, electrocardiographic and echocardiographic measures, and biological markers in these participants. In addition, they rigorously adjudicated out-of-hospital deaths to identify those most likely to be a result of fatal arrhythmias.
Deo and his colleagues identified 12 independent risk markers in their model that outperformed the 2013 ACC/AHA Pooled cohort risk equation for predicting SCD. Of note, a low left ventricular ejection fraction, which has traditionally been the primary marker for identifying high risk individuals, was present in only one percent of participants, and did not enhance SCD risk prediction.
Deo added, “Our findings provide a strong step toward distinguishing SCD risk across the general population and can help target future strategies at SCD prevention for the highest risk subgroups of the general population. What’s more, use of this risk model could lead to pinpointing specific communities with higher risk populations, ideally leading to increased training and awareness for emergency medical staff, volunteers and the general public in those regions.”
This study was funded by National Institutes of Health (K23DK089118), National Heart, Lung and Blood Institute (RC1-HL099452) (R01HL116747) (R01HL111089), and the American Heart Association (16EIA26410001), with additional contribution from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging (AG023629)
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.